Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genasense AC review

Executive Summary

Genta's chronic lymphocytic leukemia treatment Genasense will be reviewed by FDA's Oncologic Drugs Advisory Committee Sept. 6, the company said. The oblimersen injection plus chemotherapy regimen is currently pending at FDA under a standard review, with an Oct. 29 user fee date. Genta initially sought a melanoma indication, but withdrew the NDA in May 2004 following a negative advisory committee review (1"The Pink Sheet" May 24, 2004, p. 12)...

You may also be interested in...



Upcoming ODAC meetings

FDA's Oncologic Drugs Advisory Committee will review Pfizer's Fragmin (dalteparin sodium) Sept. 6 for extended treatment of symptomatic venous thromboembolism, proximal deep vein thrombosis and/or pulmonary embolism to reduce the recurrence of VTE in cancer patients. The panel will also discuss Genta's chronic lymphocytic leukemia treatment Genasense, the firm announced July 27 (1"The Pink Sheet" July 31, 2006, In Brief). Genta had initially sought a melanoma indication, but withdrew the NDA in May 2004 following a negative advisory panel review. On Sept. 7, ODAC will discuss trial design issues for Abraxis Bioscience's Abraxane for treatment of node-positive breast cancer. Abraxane originally cleared FDA January 2005 for metastatic breast cancer. The two-day meeting will be held at the Silver Spring, Md. Hilton from 8 a.m. to 5 p.m. [Editor's note: To 2watch a webcastor order a video/DVD of advisory committee meetings, visit FDAAdvisoryCommittee.com]...

Aventis, Genta To Meet With FDA After Genasense NDA Withdrawal

Aventis will participate in Genta's meeting with FDA following the withdrawal of the new drug application for Genasense

Spring Launch For Germany’s Digital Strategy

Interested parties have been consulted, workshop findings noted and online surveys completed; the drafting of Germany’s digital health strategy is now underway.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel